KRAS and neoplasm: Given a sensitive detection method in relation to the amounts of viable tumor cells, determination of the KRAS mutation status can be conducted reliably in tumor samples of the pre-therapeutic biopsy obtained at the index rectoscopy as well in the resected specimens after neoadjuvant chemoradiotherapy.